General Information of Drug (ID: DM7F1PA)

Drug Name
Nebivolol
Synonyms
Bystolic; Lobivon; Nebilet; Nebilong; Nebipill; Nebivololum; Nubeta; Nebivololum [Latin]; R 67555; Bystolic (TN); Nebicard-5;Nebilet (TN); Nebilong (TN); Nodon (TN); Nubeta (TN); PI-21858; R-67555; R65,824; Nebicard-5 (TN); Nebivolol (USAN/INN); Nebivolol [USAN:INN:BAN]; Alpha,alpha'-(Iminodimethylene)bis(6-fluoro-2-chromanmethanol); Alpha,alpha'-(Iminobis(methylene))bis(6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol); Alpha,alpha'-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol; 1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol; 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol]
Indication
Disease Entry ICD 11 Status REF
Hypertension BA00-BA04 Approved [1]
Therapeutic Class
Antihypertensive Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 405.4
Logarithm of the Partition Coefficient (xlogp) 3
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5-4 h [2]
Bioavailability
The bioavailability of drug is 12-96% [2]
Clearance
The clearance of drug is 1241.63 +/- 749.77 L/h [3]
Elimination
In extensive CYP2D6 metabolizers, 38% is eliminated in the urine and 44% in the feces [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 12 hours [4]
Metabolism
The drug is metabolized via the glucuronidation and CYP2D6 mediated hydroxylation [5]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3523 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [7]
Vd
The volume of distribution (Vd) of drug is 10,290.81 +/- 3,911.72 L [3]
Chemical Identifiers
Formula
C22H25F2NO4
IUPAC Name
1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-[[2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-2-hydroxyethyl]amino]ethanol
Canonical SMILES
C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O
InChI
InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2
InChIKey
KOHIRBRYDXPAMZ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
71301
ChEBI ID
CHEBI:64019
CAS Number
99200-09-6
DrugBank ID
DB04861
TTD ID
D0Z1UA
INTEDE ID
DR1134
ACDINA ID
D00459
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Adrenergic receptor beta-1 (ADRB1) TTR6W5O ADRB1_HUMAN Antagonist [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6)
Main DME
DECB0K3 CP2D6_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Nebivolol
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Levamlodipine DM92S6N Moderate Increased risk of cardiac depression by the combination of Nebivolol and Levamlodipine. Hypertension [BA00-BA04] [11]
Clevidipine butyrate DMW4M97 Moderate Increased risk of cardiac depression by the combination of Nebivolol and Clevidipine butyrate. Hypertension [BA00-BA04] [11]
Coadministration of a Drug Treating the Disease Different from Nebivolol (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Cariprazine DMJYDVK Moderate Additive hypotensive effects by the combination of Nebivolol and Cariprazine. Bipolar disorder [6A60] [12]
Atracurium DM42HXN Moderate Additive cardiorespiratory depression effects by the combination of Nebivolol and Atracurium. Corneal disease [9A76-9A78] [13]
Pasireotide DMHM7JS Moderate Increased risk of atrioventricular block by the combination of Nebivolol and Pasireotide. Cushing syndrome [5A70] [14]
OPC-34712 DMHG57U Moderate Additive hypotensive effects by the combination of Nebivolol and OPC-34712. Depression [6A70-6A7Z] [12]
Stiripentol DMMSDOY Moderate Decreased metabolism of Nebivolol caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [15]
Mirabegron DMS1GYT Moderate Decreased metabolism of Nebivolol caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [16]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Nebivolol caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [17]
Givosiran DM5PFIJ Moderate Decreased metabolism of Nebivolol caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [18]
Belladonna DM2RBWK Moderate Antagonize the effect of Nebivolol when combined with Belladonna. Infectious gastroenteritis/colitis [1A40] [19]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Nebivolol caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [20]
ITI-007 DMUQ1DO Moderate Additive hypotensive effects by the combination of Nebivolol and ITI-007. Insomnia [7A00-7A0Z] [12]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Nebivolol caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [19]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Nebivolol caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [21]
Vemurafenib DM62UG5 Moderate Decreased metabolism of Nebivolol caused by Vemurafenib mediated inhibition of CYP450 enzyme. Melanoma [2C30] [22]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Nebivolol due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [14]
Panobinostat DM58WKG Moderate Decreased metabolism of Nebivolol caused by Panobinostat mediated inhibition of CYP450 enzyme. Multiple myeloma [2A83] [23]
Siponimod DM2R86O Major Increased risk of bradycardia by the combination of Nebivolol and Siponimod. Multiple sclerosis [8A40] [24]
Fingolimod DM5JVAN Major Increased risk of atrioventricular block by the combination of Nebivolol and Fingolimod. Multiple sclerosis [8A40] [25]
Ozanimod DMT6AM2 Moderate Increased risk of atrioventricular block by the combination of Nebivolol and Ozanimod. Multiple sclerosis [8A40] [26]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Nebivolol caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [19]
Rolapitant DM8XP26 Moderate Decreased metabolism of Nebivolol caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [27]
Lorcaserin DMG6OYJ Moderate Decreased metabolism of Nebivolol caused by Lorcaserin mediated inhibition of CYP450 enzyme. Obesity [5B80-5B81] [28]
Methylscopolamine DM5VWOB Moderate Antagonize the effect of Nebivolol when combined with Methylscopolamine. Peptic ulcer [DA61] [19]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Nebivolol caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [29]
Silodosin DMJSBT6 Moderate Additive hypotensive effects by the combination of Nebivolol and Silodosin. Prostate hyperplasia [GA90] [30]
Iloperidone DM6AUFY Moderate Additive hypotensive effects by the combination of Nebivolol and Iloperidone. Schizophrenia [6A20] [12]
Amisulpride DMSJVAM Moderate Increased risk of ventricular arrhythmias by the combination of Nebivolol and Amisulpride. Schizophrenia [6A20] [19]
Asenapine DMSQZE2 Moderate Additive hypotensive effects by the combination of Nebivolol and Asenapine. Schizophrenia [6A20] [12]
⏷ Show the Full List of 28 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 27 E00381 83511 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Nebivolol 10 mg tablet 10 mg Oral Tablet Oral
Nebivolol 2.5 mg tablet 2.5 mg Oral Tablet Oral
Nebivolol 20 mg tablet 20 mg Oral Tablet Oral
Nebivolol 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7246).
2 FDA Approved Drug Products: Nebivolol Tablets
3 Chen CL, Desai-Krieger D, Ortiz S, Kerolous M, Wright HM, Ghahramani P: A Single-Center, Open-Label, 3-Way Crossover Trial to Determine the Pharmacokinetic and Pharmacodynamic Interaction Between Nebivolol and Valsartan in Healthy Volunteers at Steady State. Am J Ther. 2015 Sep-Oct;22(5):e130-40. doi: 10.1097/MJT.0000000000000247.
4 Rationale for nebivolol/valsartan combination for hypertension: review of preclinical and clinical data. J Hypertens. 2017 Sep;35(9):1758-1767. doi: 10.1097/HJH.0000000000001412.
5 Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep;51(9):699-725. doi: 10.1055/s-0031-1300105.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
8 Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis. 2009 Aug;3(4):317-27.
9 Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther. 2006 Aug;44(8):344-57.
10 Evaluation of 24 CYP2D6 variants on the metabolism of nebivolol in vitro. Drug Metab Dispos. 2016 Nov;44(11):1828-1831.
11 Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
12 Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
13 Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
14 Canadian Pharmacists Association.
15 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
16 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
17 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
18 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
19 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
20 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
21 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
22 Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
23 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
24 Cerner Multum, Inc. "Australian Product Information.".
25 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
26 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
27 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
28 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
29 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
30 Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]